Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genprex ( (GNPX) ) has issued an update.
On June 11, 2025, Genprex entered into a purchase agreement with Lincoln Park Capital Fund, allowing the sale of up to $12.5 million in common stock over a 24-month period, subject to certain conditions. This agreement aims to provide Genprex with working capital and support its ongoing clinical trials, which have received FDA Fast Track Designation, potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (GNPX) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Genprex stock, see the GNPX Stock Forecast page.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for cancer and diabetes. The company is engaged in clinical trials for its oncology gene therapy programs, including Acclaim-1 and Acclaim-3, which target non-small cell lung cancer and small cell lung cancer, respectively.
Average Trading Volume: 4,599,308
Technical Sentiment Signal: Sell
Current Market Cap: $8.89M
See more data about GNPX stock on TipRanks’ Stock Analysis page.